null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Lacnotuzumab ELISA Kit (GXEL00099)

SKU GXEL00099
Product Type ELISA Kit
Assay Type Quantitative
Detection Method Colorimetric
Sensitivity 0.156 μg/ml
Range 0.31-5 μg/mL
Size 96T
Synonyms MCS-110, 1831128-32-5
$1,162
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Lacnotuzumab ELISA Kit

Assay Genie's Lacnotuzumab ELISA Kit (SKU: GXEL00099) provides researchers with a reliable quantitative ELISA for the quantitative measurement of Lacnotuzumab in Plasma, Serum. Offering a measurement range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml, the kit is optimised for precision and ease of use in the research laboratory.

Lacnotuzumab, as known as MCS110, is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1 from activating the CSF-1R. The drug is being developed by Novartis Europharm Limited. On 15 October 2014, orphan designation (EU/3/14/1350) was granted by the European Commission to Novartis for recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor for the treatment of tenosynovial giant cell tumor, localized and diffuse type. They conducted a phase 1 study to assess the safety and tolerability of administering single ascending doses and repeat doses of lacnotuzumab to healthy volunteers, and to examine the pharmacokinetics (PK), pharmacodynamics (PD), and mechanistic properties of lacnotuzumab. Nonclinical investigations of the mechanism of action of lacnotuzumab were also performed to explain the observed adverse events (AEs) profile associated with CSF-1 pathway inhibition. Lacnotuzumab was generally well tolerated. The majority of AEs were low grade, no unexpected or novel AEs were observed, and there were no discontinuations for AEs. Lacnotuzumab also showed dose-dependent, on-target effects on multiple downstream biomarkers. Preclinical investigations of the CK elevation and periorbital swelling observed after lacnotuzumab administration suggest that these are reversible, nonpathological events linked to inhibition of the CSF-1 pathway. These data support further evaluation of lacnotuzumab in clinical studies.

Complete with standards, buffers and detection reagents, the Lacnotuzumab ELISA Kit streamlines assay set-up so you can focus on results. Choose the Lacnotuzumab ELISA Kit from Assay Genie for quality you can trust.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose